drug development - search results

Lorna Rothery spoke to the Cancer Drug Development Forum’s Managing Director, Professor Jaap Verweij and Chairperson of the CDDF Board of Directors, Professor Ruth Plummer, about opportunities and challenges in oncology research and treatment.

Jaap Verweij, M.D., Ph.D is an Emeritus Professor of Medical Oncology, and former Dean of the Faculty of Medicine at Erasmus University Medical Centre He served as chair of the Department of Medical Oncology, and chair of the Daniel den Hoed Cancer Center at the Erasmus University Medical Centre from...

Ruth Plummer is a Professor of Experimental Cancer Medicine in the Translational and Clinical Research Institute, Newcastle University, and an honorary consultant medical oncologist in Newcastle Hospitals NHS Foundation Trust. Prof. Plummer is director of the Sir Bobby Robson Cancer Trials Research Centre within the Northern Centre for Cancer Care....

A new drug development could help those battling pancreatic cancer, one of the most challenging cancers to treat.

Eric Buckland of Translational Imaging Innovations looks at ophthalmic drug development and how better clinical endpoints can improve success rates.

Can Artificial Intelligence (AI) change the process of drug development for the pharmaceutical industry?

New research shows that the gender gap in drug development trials results in an overmedication of women by healthcare professionals.

Open Access Government (May 2018) "Thanks for the information. We have already tweeted and shared the article with our contacts. Thanks for this opportunity and feel free to contact me should you have future editions on the topic of cancer."   Marjorie Recorbet, The Cancer Drug Development Forum – CDDF

Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University explores a novel approach to Ph.D. training for those in the pharmaceutical industry

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

David H Peyton at Portland State University outlines how research has discovered that heme is key to malaria drug development

Professor Duncan McHale, Head Global Exploratory Development at UCB discusses the challenge of developing drugs to treat neurodegenerative diseases

David H Peyton at Portland State University outlines how research has discovered that heme is key to malaria drug development

Prof. Dr. Tanja Gaich, of the University of Konstanz – Department of Chemistry discusses new strategies in drug development and the challenges involved

SIOPE asks why therapies made available for adults are not extended to children with cancer, and why paediatric oncology drug development is lagging behind Thanks to the increasing introduction of molecular targeting and personalised medicine strategies, innovative medicines and treatments are nowadays available for adults with cancer. Widespread access to...

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

Sumith A Kularatne, Vice President of Research and Development at On Target Laboratories shares the research strides he has made in drug development

Professor Duncan McHale, Head Global Exploratory Development, UCB discusses reclassifying neurodegenerative diseases to enable drug development and to help patients... Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer.  By 2020 there will be more than 40 million individuals in the world with Alzheimer’s disease and...

Ramón Cacabelos, of EuroEspes Biomedical Research Center discusses the strides being made in drug development for Alzheimer's disease... Alzheimer’s disease (AD) is a major problem of health and a national priority in developed countries. Despite enormous efforts by governments, the scientific community and the pharmaceutical industry over the past 50 years,...

Alzheimer's disease (AD) is a major problem of health and a national priority in developed countries. Despite enormous efforts by governments, the scientific community and the pharmaceutical industry over the past 50 years, no therapeutic breakthroughs have yet been achieved, and the drugs available for the treatment of AD...